- Home
- CZNC vs ALT Comparison
CZNC vs ALT Comparison
Compare CZNC & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CZNC | ALT |
|---|---|---|
| Founded | 1864 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 360.7M | 415.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CZNC | ALT |
|---|---|---|
| Price | $19.93 | $3.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $22.00 | $16.33 |
| AVG Volume (30 Days) | 78.6K | ★ 4.8M |
| Earning Date | 01-22-2026 | 11-06-2025 |
| Dividend Yield | ★ 5.55% | N/A |
| EPS Growth | ★ 22.09 | N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $109,632,000.00 | $20,000.00 |
| Revenue This Year | $5.72 | N/A |
| Revenue Next Year | $7.18 | N/A |
| P/E Ratio | $11.51 | ★ N/A |
| Revenue Growth | ★ 7.59 | N/A |
| 52 Week Low | $17.85 | $2.90 |
| 52 Week High | $22.68 | $7.83 |
Technical Indicators
Market Signals| Indicator | CZNC | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 38.05 | 29.99 |
| Support Level | $20.46 | $3.83 |
| Resistance Level | $22.25 | $5.37 |
| Average True Range (ATR) | 0.49 | 0.31 |
| MACD | -0.21 | -0.17 |
| Stochastic Oscillator | 4.92 | 0.59 |
Price Performance
Historical ComparisonAbout CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.